Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s First Insulin Tender Hits Multinationals Hard

Executive Summary

An average overall price reduction of 48% for insulin products in China is expected to generate annual savings of $1.4bn through 2023, but multinational pharma firms will be hit hard by the bidding process.

You may also be interested in...



Asia Deal Watch: Nippon Shinyaku Acquires US Rights To Capricor’s DMD Drug

Plus deals involving Aculys/Neurelis, Xtalpi/Excelra, Abbisko/Lilly, Daiichi Sankyo/Cosette, Mitsubishi Tanabe/ADC Therapeutics and PersonGen/Transgene.

China Biotechs Bag $740m As Ox Makes Way For Tiger

With the Lunar New Year just around the corner, Chinese biotechs have raised a total of $740m through initial public offerings and 10 other fundraising deals.

Recbio First Biotech To Brave A Hong Kong IPO In 2022

Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel